on NOVACYT (EPA:ALNOV)
Novacyt Announces the Publication of its First Half 2025 Results
Novacyt SA, a molecular diagnostics company, announced that it will release its unaudited financial results for the six months ended June 30, 2025, on September 30. Listed on Euronext Growth and AIM, Novacyt offers a broad range of integrated technologies and services. Its business is divided into three segments: Clinical, Instrumentation, and Research Use. Within the Clinical segment, the company offers in vitro diagnostics for reproductive health, precision medicine, and infectious diseases. The financial results will provide guidance on the company's half-year performance.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all NOVACYT news